Kornitzer Capital Management Inc. KS Has $2.75 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Kornitzer Capital Management Inc. KS reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 58.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 21,052 shares of the life sciences company's stock after selling 29,380 shares during the period. Kornitzer Capital Management Inc. KS's holdings in Illumina were worth $2,745,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its position in Illumina by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company's stock worth $2,505,409,000 after buying an additional 66,528 shares during the period. Bank of New York Mellon Corp raised its stake in Illumina by 7.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company's stock valued at $317,267,000 after purchasing an additional 204,043 shares during the last quarter. Capital World Investors raised its stake in Illumina by 41.1% during the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company's stock valued at $378,111,000 after purchasing an additional 801,814 shares during the last quarter. Primecap Management Co. CA boosted its holdings in Illumina by 462.5% in the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company's stock valued at $253,514,000 after purchasing an additional 1,997,010 shares during the period. Finally, GUARDCAP ASSET MANAGEMENT Ltd grew its position in Illumina by 1.1% in the 1st quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 2,068,869 shares of the life sciences company's stock worth $284,097,000 after purchasing an additional 22,067 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

ILMN traded down $4.06 during midday trading on Friday, hitting $151.09. The company had a trading volume of 2,209,599 shares, compared to its average volume of 1,772,358. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $156.66. The company has a market capitalization of $24.07 billion, a PE ratio of -15.17 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a quick ratio of 0.86 and a current ratio of 2.43. The firm's 50-day simple moving average is $138.09 and its 200-day simple moving average is $123.56.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same quarter last year, the business posted $0.33 earnings per share. Illumina's revenue for the quarter was down 3.5% compared to the same quarter last year. Equities research analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Daiwa Capital Markets upgraded shares of Illumina from a "neutral" rating to a "buy" rating and increased their target price for the company from $120.00 to $154.00 in a research note on Friday, August 16th. HSBC upgraded Illumina from a "hold" rating to a "buy" rating and set a $180.00 price objective for the company in a research report on Thursday, October 17th. Hsbc Global Res upgraded Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. TD Cowen raised their target price on Illumina from $166.00 to $177.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, Leerink Partners boosted their price target on shares of Illumina from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Illumina currently has a consensus rating of "Moderate Buy" and a consensus target price of $162.18.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.